 | |
| Clinical data | |
|---|---|
| Trade names | Gavreto |
| Other names | BLU-667 |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a620057 |
| License data | |
| Pregnancy category | |
| Routes of administration | By mouth |
| Drug class | Tyrosine kinase inhibitor |
| ATC code | |
| Legal status | |
| Legal status | |
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEMBL | |
| Chemical and physical data | |
| Formula | C27H32FN9O2 |
| Molar mass | 533.612 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Pralsetinib, sold under the brand nameGavreto, is amedication approved[10] for RET mutation-positive medullary thyroid cancer (MTC)[11] and RET fusion-positive differentiatedthyroid cancer (DTC) refractory to radioactive iodine (RAI) therapy.[12] Pralsetinib is atyrosine kinase inhibitor. It is takenby mouth.[12]
The most common adverse reactions include increasedaspartate aminotransferase (AST), decreasedhemoglobin, decreasedlymphocytes, decreasedneutrophils, increasedalanine aminotransferase (ALT), increased creatinine, increased alkaline phosphatase, fatigue, constipation, musculoskeletal pain, decreased calcium, hypertension, decreased sodium, decreased phosphate, and decreased platelets.[12]
Pralsetinib was approved for medical use in the United States in September 2020,[12][13][14][15][16][excessive citations] and in the European Union in November 2021.[8]
Pralsetinib is indicated for the treatment of adults with metastatic RET fusion-positive non-small cell lung cancer (NSCLC) as detected by an FDA approved test.[12][15]
Efficacy was investigated in a multicenter, open-label, multi-cohort clinical trial (ARROW, NCT03037385) with 220 participants aged 26-87 whose tumors had RET alterations.[12][15] Identification of RET gene alterations was prospectively determined in local laboratories using either next generation sequencing, fluorescence in situ hybridization, or other tests.[12] The main efficacy outcome measures were overall response rate (ORR) and response duration determined by a blinded independent review committee using RECIST 1.1.[12] The trial was conducted at sites in the United States, Europe and Asia.[15]
Efficacy for RET fusion-positive NSCLC was evaluated in 87 participants previously treated with platinum chemotherapy.[12] The ORR was 57% (95% CI: 46%, 68%); 80% of responding participants had responses lasting 6 months or longer.[12] Efficacy was also evaluated in 27 participants who never received systemic treatment.[12] The ORR for these participants was 70% (95% CI: 50%, 86%); 58% of responding participants had responses lasting 6 months or longer.[12]
The USFood and Drug Administration (FDA) granted the application for pralsetinibpriority review,orphan drug, andbreakthrough therapy designations[12]and granted approval of Gavreto to Blueprint Medicines.[12]
On 16 September 2021, theCommittee for Medicinal Products for Human Use (CHMP) of theEuropean Medicines Agency (EMA) adopted a positive opinion, recommending the granting of a conditional marketing authorization for the medicinal product Gavreto, intended for the treatment of people with rearranged during transfection (RET)-fusion positive non-small cell lung cancer (NSCLC).[17] The applicant for this medicinal product is Roche Registration GmbH.[17] Pralsetinib was approved for medical use in the European Union in November 2021.[8]
This article incorporates text from this source, which is in thepublic domain. This article incorporates text from this source, which is in thepublic domain.